AN2 Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 64.73 million compared to USD 40.96 million a year ago. Basic loss per share from continuing operations was USD 2.74 compared to USD 2.79 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 USD | +2.16% | +0.42% | -88.43% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.43% | 69.2M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- ANTX Stock
- News AN2 Therapeutics, Inc.
- AN2 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023